Time filter

Source Type

Zürich, Switzerland

Van Hemelrijck M.,Kings College London | Feller A.,Foundation National Institute for Cancer Epidemiology and Registration NICER | Feller A.,University of Bern | Garmo H.,Kings College London | And 4 more authors.
PLoS ONE | Year: 2014

Introduction: There is a need to assess risk of second primary cancers in prostate cancer (PCa) patients, especially since PCa treatment may be associated with increased risk of second primary tumours. Methods: We calculated standardized incidence ratios (SIRs) for second primary tumours comparing men diagnosed with PCa between 1980 and 2010 in the Canton of Zurich, Switzerland (n = 20,559), and the general male population in the Canton. Results: A total of 1,718 men developed a second primary tumour after PCa diagnosis, with lung and colon cancer being the most common (15 and 13% respectively). The SIR for overall second primary cancer was 1.11 (95%CI: 1.06-1.17). Site-specific SIRs varied from 1.19 (1.05-1.34) to 2.89 (2.62-4.77) for lung and thyroid cancer, respectively. When stratified by treatment, the highest SIR was observed for thyroid cancer (3.57 (1.30-7.76)) when undergoing surgery, whereas liver cancer was common when treated with radiotherapy (3.21 (1.54-5.90)) and kidney bladder was most prevalent for those on hormonal treatment (3.15 (1.93-4.87)). Stratification by time since PCa diagnosis showed a lower risk of cancer for men with PCa compared to the general population for the first four years, but then a steep increase in risk was observed. Conclusion: In the Canton of Zurich, there was an increased risk of second primary cancers among men with PCa compared to the general population. Increased diagnostic activity after PCa diagnosis may partly explain increased risks within the first years of diagnosis, but time-stratified analyses indicated that increased risks remained and even increased over time. © 2014 Van Hemelrijck et al. Source

Prater J.,Cancer Registry Zurich and Zug | Valeri F.,Cancer Registry Zurich and Zug | Valeri F.,University of Zurich | Korol D.,Cancer Registry Zurich and Zug | Dehler S.,Cancer Registry Zurich and Zug
Journal of Cancer Research and Clinical Oncology | Year: 2016

Purpose: To examine the incidence and characteristics of metachronous contralateral breast cancer (CBC) among women in the Canton of Zurich, Switzerland. Methods: For 1980–2006, patients with unilateral invasive breast cancer (UBC) were analysed for metachronous CBC. Poisson’s regression was used to estimate incidence rates of metachronous CBC according to age, year of diagnosis, follow-up period since first breast cancer and morphology. Results: Of 16,323 patients with UBC, 700 (4.3 %) developed a second malignant tumour of the opposite breast. Median age at first breast cancer was lower in the CBC group than in the full cohort. Median interval time between first and second breast cancer was 5.5 (interquartile range 2.6–10.1) years. Incidence rate at age 20–29 was 1006 (95 % confidence interval, CI, 452–2238) cases per 100,000 person-years and decreased to 299 (199–450) at 80–84. Age-adjusted incidence rates according to period of diagnosis decreased from 618 (530–721) for 1980–1984 to 329 (217–500) cases per 100,000 person-years for 2005–2006. Incidence rate ratio of CBC for lobular carcinoma was 1.28 (95 % CI 0.99–1.67) adjusted by age group and period of diagnosis compared to ductal carcinoma. Conclusions: In our study, incidence rates for CBC are comparable with findings from the literature. A reduction in the incidence of metachronous CBC, thought to be due to adjuvant therapies, is seen in our data. In our cohort, younger age and lobular carcinoma were associated with an increased risk of CBC. © 2015, Springer-Verlag Berlin Heidelberg. Source

Discover hidden collaborations